Objective: gliomas are the most com-mon intracranial tumors. Fibroblast growth factor-12 (FGF12), which belongs to the fibroblast growth factor (FGFs) family, plays an important role in cell mitosis, as well as in other life functions, such as embryo develop-ment, tissue repair, cell proliferation, and tumor growth and invasion. The purpose of this study was to explore the potential value of FGF12 in high-grade gliomas and to predict its drug sensitivity. To provide a possible ther-apeutic target for glioma. Methods: high-grade glioma gene expression data and clinical information were down-loaded from the gene expression omnibus (GEO) data-base, using the R language “impute” and “survival” sur-vival analysis package. The FGF12 genes closely related to survival were screened, a survival curve was drawn, and clinical correlation analysis was conducted. The differentially expressed genes (DEGs) were defined as |logFC|> 1, adj. PVal < 0.05 as the standard. We used the David for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and constructed the protein-protein interactions (PPI) network. Then we used the Connectivity Map (CMAP) database for drug lo-cation, and the validation group was verified by the Chi-nese Glioma Genome Atlas (CGGA) database in the same way. Results: we found that high FGF12 expression was associated with a higher survival rate. The same valida-tion was performed in the validation group through the CGGA database, and the survival curve showed the same trend. The expression level of FGF12 is an independent factor that affects the life time and status of the samples, and it is a low risk factor. GO enrichment analysis showed that differential genes were enriched in matrix transmem-brane transporter activity, ion channels and calcium ion active channels. KEGG showed that DEGs were enriched in the phosphatidylinositol 3-kinase (PI3K)-protein ki-nase B (Akt) signaling pathway, dopaminergic synapse and cyclic adenosine monophosphate (cAMP) signaling pathway. Four seed genes, GRIA2, COLLA2, GRIA4 and HES6, were obtained by PPI network analysis. The cAMP was used to analyze and obtained 7 small molecule drugs, such as merbromin, naloxone, AH-23848, ticarcillin, vin-camine, amoxicillin, azacyclonol, which may be helpful in the prognosis of high-grade gliomas. Conclusion: FGF12 and its pathway may serve as a biomarker or ther-apeutic target for high-grade gliomas.